XACT robotic system is designed to insert and steer different instruments during percutaneous interventional procedures. Credit: Sasin Tipchai from Pixabay.

The US Food and Drug Administration (FDA) has granted marketing clearance to XACT Robotics’ hands-free robotic system for use in computed tomography (CT) guided percutaneous interventional procedures.

The system uses a combination of image-based planning and navigation tools to insert and steer different instruments to the target location within the body.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The system can be used in an array of clinical applications and indications, according to Xact Robotics.

Furthermore, the robotic system’s relatively small footprint and mobile design allow care providers to cater to a variety of patient needs across multiple clinical areas, the company added.

XACT Robotics founder, executive chairman and president Harel Gadot said: “We are committed to redefining the way the entire medical community utilises robotics, beginning with interventional radiologists.

“Being the first to introduce a hands-free robotic system, we have the potential to provide significant clinical, technical and economic value while democratising interventional procedures.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The XACT Robotic System is designed based on research by the Technion, Israel Institute of Technology professor Moshe Shoham, who founded Mazor Robotics, which was acquired by Medtronic last year.

A physician can use the XACT robot by attaching the desired tool to the system, which will perform the needle insertion and steering. The physician will be able to track the progress and correct any deviations.

The company noted that the system, which secured the European CE-Mark last year, compensates for breathing and patient movement during the procedure.

XACT intends to launch the system to some US radiology Centers of Excellence partners and debut it next month at the 2019 Radiological Society of North America conference (RSNA) in Chicago, US.

Last year, the company raised $5m in a Series C funding round to support the system’s launch in Europe, the US and Israel.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact